105 related articles for article (PubMed ID: 24680060)
1. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.
Awahara C; Tatsumi T; Furuta S; Shinjoh G; Konno H; Nosaka K; Kobayashi K; Hattori Y; Akaji K
Bioorg Med Chem; 2014 Apr; 22(8):2482-8. PubMed ID: 24680060
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster.
Tatsumi T; Awahara C; Naka H; Aimoto S; Konno H; Nosaka K; Akaji K
Bioorg Med Chem; 2010 Apr; 18(7):2720-7. PubMed ID: 20226680
[TBL] [Abstract][Full Text] [Related]
3. Evaluating a Retro-Inverso Type Inhibitor of HTLV-1 Protease as a Competitive Inhibitor.
Awahara C; Oku D; Kobayashi K; Hattori Y
Chem Pharm Bull (Tokyo); 2024; 72(3):309-310. PubMed ID: 38479891
[TBL] [Abstract][Full Text] [Related]
4. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
Kuhnert M; Blum A; Steuber H; Diederich WE
J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
[TBL] [Abstract][Full Text] [Related]
5. Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease.
Naka H; Teruya K; Bang JK; Aimoto S; Tatsumi T; Konno H; Nosaka K; Akaji K
Bioorg Med Chem Lett; 2006 Jul; 16(14):3761-4. PubMed ID: 16682197
[TBL] [Abstract][Full Text] [Related]
6. The Effects of Side-Chain Configurations of a Retro-Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease.
Awahara C; Oku D; Furuta S; Kobayashi K; Teruya K; Akaji K; Hattori Y
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268749
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.
Selvaraj C; Singh P; Singh SK
J Mol Recognit; 2014 Dec; 27(12):696-706. PubMed ID: 25319617
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease.
Satoh T; Li M; Nguyen JT; Kiso Y; Gustchina A; Wlodawer A
J Mol Biol; 2010 Aug; 401(4):626-41. PubMed ID: 20600105
[TBL] [Abstract][Full Text] [Related]
9. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
10. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
11. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
[TBL] [Abstract][Full Text] [Related]
13. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.
Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y
J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213
[TBL] [Abstract][Full Text] [Related]
14. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
15. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
Maegawa H; Kimura T; Arii Y; Matsui Y; Kasai S; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2004 Dec; 14(23):5925-9. PubMed ID: 15501070
[TBL] [Abstract][Full Text] [Related]
16. Human T-cell leukemia virus type 1 protease protein expressed in Escherichia coli possesses aspartic proteinase activity.
Saiga A; Tanaka T; Orita S; Sato A; Sato S; Hachisu T; Abe K; Kimura Y; Kondo Y; Fujiwara T
Arch Virol; 1993; 128(3-4):195-210. PubMed ID: 8435041
[TBL] [Abstract][Full Text] [Related]
17. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.
Daenke S; Schramm HJ; Bangham CR
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922
[TBL] [Abstract][Full Text] [Related]
18. Understanding HTLV-I protease.
Shuker SB; Mariani VL; Herger BE; Dennison KJ
Chem Biol; 2003 May; 10(5):373-80. PubMed ID: 12770819
[No Abstract] [Full Text] [Related]
19. Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease.
Ma S; Vogt KA; Petrillo N; Ruhoff AJ
Comput Biol Chem; 2015 Jun; 56():61-70. PubMed ID: 25889320
[TBL] [Abstract][Full Text] [Related]
20. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 Jul; 16(14):6880-90. PubMed ID: 18558491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
